Biotechnology company Apogee Therapeutics raised USD 149 in an oversubscribed Series B funding round co-led by Deep Track Capital and RTW Investments, with participation from new and existing investors, including funds and accounts advised by Fidelity Management & Research Company, OrbiMed, and RA Capital Management. This brings the total funds raised by the company to USD 169 million.
The new funds will be used to advance its lead program to clinical trials in 2023 and to expand its human resources including its leadership, scientific, and clinical teams.
Founded in 2022, Apogee Therapeutics is a spin-off from Paragon Therapeutics and has a strategic collaboration with Paragon with exclusive rights to develop and commercialize antibodies. The company focuses on discovering and developing drugs targeting biological pathways to treat patients with immunological and inflammatory conditions. Further, the company plans to submit at least one Investigational New Drug application with the FDA for each year over three years starting in 2023. It has four programs in the pipeline and expects to release more information in 2023.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.